Tag: lung cancer

Active  name: ENSARTINIB HYDROCHLORIDE Brand name: ENSACOVE Innovator name XCOVERY HOLDINGS INC Approval Date: Dec 18, 2024 Therapeutic activity:   ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Route of administration Capsule, oral Structure Chemical name 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-{4-[(3R,5S)- 3,5-dimethylpiperazine-1-carbonyl]phenyl}pyridazine-3-carboxamide, dihydrochloride CAS […]